ABSTRACT
Introduction: For many years, applications for baclofen have widened in the treatment of substance abuse disorder (SUD), mainly alcohol use disorder, with a growing rate of off-label prescriptions in Europe. Clinical effects seem to be both a decrease of craving and anxiety, leading to a decrease of drug or alcohol consumption. We described baclofen poisoning circumstances, therapeutic options and outcomes when used in substance use disorders.Areas covered: This review summarizes the toxicological considerations where baclofen was prescribed in humans for substance use or abuse disorder in randomized clinical trials, case series, case reports and observational studies between 1990 and 2020 according to the Preferred Reporting Items for Systemic reviews and Meta-Analysis.Expert opinion: The most frequent cause of severe intoxication is self-poisoning. A dose above 180 mg are expected to cause severe toxicity and death. The treatment is only symptomatic as no antidote is available. Off-label prescription remains unsafe because the optimal dose is not known and varies greatly between patients. As SUD are frequently associated with psychiatric disorders and such patients may have suicidal thoughts, the risk of self-poisoning is high. Potential co-ingestants should also be considered, especially CNS depressants, and they need to be closely monitored.
Subject(s)
Alcoholism/drug therapy , Baclofen/poisoning , Substance-Related Disorders/drug therapy , Baclofen/administration & dosage , Baclofen/adverse effects , Dose-Response Relationship, Drug , GABA-B Receptor Agonists/administration & dosage , GABA-B Receptor Agonists/adverse effects , GABA-B Receptor Agonists/poisoning , Humans , Off-Label Use , Randomized Controlled Trials as Topic , Suicide, AttemptedABSTRACT
Baclofen is often prescribed in high doses to fight cravings experienced by alcohol-dependent patients. Such an increase in the availability of baclofen is concerning. This study aimed to determine the change in number and profile of self-poisoning with baclofen over time, as baclofen has become increasingly popular, in order to describe the severity of self-poisoning with baclofen and to focus on co-existing alcohol use disorders, and psychiatric illnesses determine predictors of severity. This was a retrospective study of self-poisoning with baclofen as reported by the western France Poison Control Center (PCC), which represents a population of more than 12 million people from January 2008 to March 2014. One hundred and eleven cases of self-poisoning with baclofen were reported to the western France PCC (62 males and 49 females; average age 39 ± 12). Poisoning severities were as follows: 'null' (nine cases), 'minor' (37 cases), 'moderate' (19 cases) and 'high' (46 cases, including four deaths). The most frequently reported symptoms were neurological (45%) and cardiovascular (27%). The severity was significantly associated with psychiatric disorders (OR = 2.9; p = 0.03). Baclofen, prescribed in high doses, may lead to severe poisoning, particularly in patients with psychiatric illnesses. Authorities should put forward a new policy for prescribing the drug as a treatment for alcohol dependence.
Subject(s)
Alcoholism/drug therapy , Baclofen/poisoning , Cardiovascular Diseases/chemically induced , GABA-B Receptor Agonists/poisoning , Neurotoxicity Syndromes/etiology , Adult , Alcoholism/psychology , Cardiovascular Diseases/diagnosis , Craving/drug effects , Female , France , Humans , Male , Middle Aged , Neurotoxicity Syndromes/diagnosis , Off-Label Use , Poison Control Centers , Polypharmacy , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time FactorsABSTRACT
BACKGROUND: Baclofen is increasingly prescribed for alcohol dependency. Subsequently, the risk of self-intoxication with this medicinal product is increasing. CASE DESCRIPTION: A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine. Respiratory insufficiency as a result of the baclofen intoxication required intubation and admission to the ICU. During the first day, despite the use of sedatives, the patient became intermittently agitated and aggressive. In the following days, he developed severe delirium, probably due to baclofen withdrawal. The reintroduction of baclofen quickly resolved these symptoms. CONCLUSION: In the case of baclofen, in practice it is difficult to differentiate between intoxication and withdrawal. To prevent potentially severe withdrawal symptoms, we recommend reintroduction of baclofen when the first signs of restlessness and agitation arise following intoxication.
Subject(s)
Aggression/psychology , Alcoholism/drug therapy , Baclofen/poisoning , Drug Overdose/complications , Psychomotor Agitation/etiology , Substance Withdrawal Syndrome/complications , Adult , Delirium/chemically induced , GABA-B Receptor Agonists/poisoning , Humans , Male , Mianserin/analogs & derivatives , Mirtazapine , Respiratory Insufficiency/chemically induced , Young AdultABSTRACT
Baclofen has been increasingly used in the treatment of alcohol withdrawal syndrome (AWS). We present a patient with AWS and psychiatric comorbidity who ingested 700 mg of baclofen. ICU admission was necessary for ventilatory support and symptomatic treatment. The patient was dismissed without sequelae.
Subject(s)
Alcoholism/drug therapy , Baclofen/poisoning , GABA-B Receptor Agonists/poisoning , Panic Disorder/drug therapy , Diagnosis, Dual (Psychiatry) , Female , Humans , Middle Aged , Poisoning/therapy , Risk FactorsABSTRACT
Used in the treatment of spasticity at low doses, baclofen is also prescribed off-label at high doses for the treatment of alcohol dependence. Several cases of baclofen intoxication have been reported, but only 1 case deals with the treatment of alcohol dependence. Thus, we report the first death in the context of baclofen off-label use of an alcohol-dependent patient with a high blood baclofen concentration after intentional drug intoxication. The safety profile of baclofen in the treatment of alcohol dependence is reviewed and discussed, underlining the obligatory caution that may support any prescription of high doses of baclofen in this off-label indication and especially in patients with concomitant psychiatric disorders.
